Tristel profit falls; lifts dividend as patient examinations recover

Writer,

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Infection prevention product manufacturer Tristel booked a fall in annual profit, citing the impact of the pandemic, but still upped its dividend.

Pre-tax profit for the year through June dropped to £3.8 million, down from £6.6 million year-on-year, as revenue slipped 2% to £31.0 million.

Tristel hiked its full-year dividend to 6.55p per share, up 6% year-on-year.

'The year was a disappointing one for the company,' chief executive Paul Swinney said.

'The top-line and profits growth trajectory we have been on since 2013 was impacted significantly by Covid-19 and the unprecedented challenges it brought.'

'We are confident that we will re-boot our progress this year as hospitals worldwide return to pre-pandemic levels of patient examinations.'